Orbimed Advisors Llc Sells 2,948 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 2,948 shares of the company’s stock in a transaction that occurred on Saturday, April 18th. The stock was sold at an average price of $44.52, for a total value of $131,244.96. Following the transaction, the director directly owned 2,964,774 shares in the company, valued at $131,991,738.48. The trade was a 0.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.68, for a total value of $2,341,097.96.
• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total value of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.51, for a total value of $2,128,201.14.
• On Tuesday, February 3rd, Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total value of $1,295,628.54.
• On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.57, for a total value of $84,237.30.

Sionna Therapeutics Stock Up 3.4%

Shares of NASDAQ:SION opened at $43.20 on Thursday. Sionna Therapeutics, Inc. has a twelve month low of $10.97 and a twelve month high of $46.46. The stock’s 50 day moving average is $38.07 and its 200-day moving average is $38.66. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -22.15 and a beta of 3.01.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15. Equities research analysts anticipate that Sionna Therapeutics, Inc. will post -2.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Raymond James Financial reissued a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a research report on Monday, January 5th. Citigroup assumed coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an “outperform” rating for the company. BTIG Research reissued a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Finally, UBS Group reissued a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $50.57.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Viking Global Investors LP grew its stake in Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares during the period. Vanguard Group Inc. grew its stake in Sionna Therapeutics by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares during the period. Jennison Associates LLC grew its stake in Sionna Therapeutics by 11.8% in the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after purchasing an additional 117,903 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Sionna Therapeutics by 30.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock valued at $34,203,000 after purchasing an additional 193,613 shares during the period. Finally, State Street Corp grew its stake in Sionna Therapeutics by 188.7% in the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after purchasing an additional 453,196 shares during the period.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.